Case Report
Published on 31 Oct 2022
ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
in Cancer Molecular Targets and Therapeutics
- 1,897 views
- 4 citations
Case Report
Published on 31 Oct 2022
in Cancer Molecular Targets and Therapeutics
Systematic Review
Published on 31 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 31 Oct 2022
in Cancer Molecular Targets and Therapeutics
Case Report
Published on 31 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 27 Oct 2022
in Cancer Molecular Targets and Therapeutics
Case Report
Published on 26 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 26 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 24 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 24 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 21 Oct 2022
in Cancer Molecular Targets and Therapeutics
Review
Published on 21 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 20 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 19 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 14 Oct 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 13 Oct 2022
in Cancer Molecular Targets and Therapeutics
Technology and Code
Published on 13 Oct 2022
in Cancer Molecular Targets and Therapeutics